title: Vedolizumab and Infliximab Combination Therapy in the Treatment of Crohn's Disease.
authors.affiliation: Division of Gastroenterology, Hofstra North Shore-LIJ School of Medicine, North Shore-Long Island Jewish Health System, New Hyde Park, New York, USA.
authors.forename: Robert
authors.initials: R
authors.lastname: Hirten
authors.affiliation: Division of Gastroenterology and Hepatology, Weill Cornell Medical College-New York Presbyterian Hospital, New York, New York, USA.
authors.forename: Randy S
authors.initials: RS
authors.lastname: Longman
authors.affiliation: Division of Gastroenterology and Hepatology, Weill Cornell Medical College-New York Presbyterian Hospital, New York, New York, USA.
authors.forename: Brian P
authors.initials: BP
authors.lastname: Bosworth
authors.affiliation: Division of Gastroenterology and Hepatology, Weill Cornell Medical College-New York Presbyterian Hospital, New York, New York, USA.
authors.forename: Adam
authors.initials: A
authors.lastname: Steinlauf
authors.affiliation: Division of Gastroenterology and Hepatology, Weill Cornell Medical College-New York Presbyterian Hospital, New York, New York, USA.
authors.forename: Ellen
authors.initials: E
authors.lastname: Scherl
mesh_terms: D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D003424:Crohn Disease / Q000175:diagnosis* / Q000188:drug therapy* / Q000473:pathology; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D000069285:Infliximab / Q000627:therapeutic use*; D008297:Male; D000069442:Natalizumab / Q000627:therapeutic use; D012074:Remission Induction; D012812:Sigmoidoscopy; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D005765:Gastrointestinal Agents; D000069442:Natalizumab; D014409:Tumor Necrosis Factor-alpha; C543529:vedolizumab; D000069285:Infliximab